BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 38493257)

  • 1. The novel drug candidate S2/IAPinh improves survival in models of pancreatic and ovarian cancer.
    Hagi T; Vangveravong S; Takchi R; Gong Q; Goedegebuure SP; Tiriac H; Van Tine BA; Powell MA; Hawkins WG; Spitzer D
    Sci Rep; 2024 Mar; 14(1):6373. PubMed ID: 38493257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conjugation to a SMAC mimetic potentiates sigma-2 ligand induced tumor cell death in ovarian cancer.
    Garg G; Vangveravong S; Zeng C; Collins L; Hornick M; Hashim Y; Piwnica-Worms D; Powell MA; Mutch DG; Mach RH; Hawkins WG; Spitzer D
    Mol Cancer; 2014 Mar; 13():50. PubMed ID: 24602489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The targeted SMAC mimetic SW IV-134 augments platinum-based chemotherapy in pre-clinical models of ovarian cancer.
    Binder PS; Hashim YM; Cripe J; Buchanan T; Zamorano A; Vangveravong S; Mutch DG; Hawkins WG; Powell MA; Spitzer D
    BMC Cancer; 2022 Mar; 22(1):263. PubMed ID: 35279106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sigma-2 receptor ligand as a novel method for delivering a SMAC mimetic drug for treating ovarian cancer.
    Zeng C; Vangveravong S; McDunn JE; Hawkins WG; Mach RH
    Br J Cancer; 2013 Oct; 109(9):2368-77. PubMed ID: 24104966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted pancreatic cancer therapy with the small molecule drug conjugate SW IV-134.
    Hashim YM; Spitzer D; Vangveravong S; Hornick MC; Garg G; Hornick JR; Goedegebuure P; Mach RH; Hawkins WG
    Mol Oncol; 2014 Jul; 8(5):956-67. PubMed ID: 24731702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Targeted SMAC Mimetic SW IV-134 is a strong enhancer of standard chemotherapy in pancreatic cancer.
    Hashim YM; Vangveravong S; Sankpal NV; Binder PS; Liu J; Goedegebuure SP; Mach RH; Spitzer D; Hawkins WG
    J Exp Clin Cancer Res; 2017 Jan; 36(1):14. PubMed ID: 28095907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Smac peptide potentiates TRAIL- or paclitaxel-mediated ovarian cancer cell death in vitro and in vivo.
    Mao HL; Pang Y; Zhang X; Yang F; Zheng J; Wang Y; Liu P
    Oncol Rep; 2013 Feb; 29(2):515-22. PubMed ID: 23151974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent and selective small-molecule inhibitors of cIAP1/2 proteins reveal that the binding of Smac mimetics to XIAP BIR3 is not required for their effective induction of cell death in tumor cells.
    Sun H; Lu J; Liu L; Yang CY; Wang S
    ACS Chem Biol; 2014 Apr; 9(4):994-1002. PubMed ID: 24521431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LCL161 increases paclitaxel-induced apoptosis by degrading cIAP1 and cIAP2 in NSCLC.
    Yang C; Wang H; Zhang B; Chen Y; Zhang Y; Sun X; Xiao G; Nan K; Ren H; Qin S
    J Exp Clin Cancer Res; 2016 Sep; 35(1):158. PubMed ID: 27737687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum-resistant or -refractory epithelial ovarian cancer.
    Noonan AM; Bunch KP; Chen JQ; Herrmann MA; Lee JM; Kohn EC; O'Sullivan CC; Jordan E; Houston N; Takebe N; Kinders RJ; Cao L; Peer CJ; Figg WD; Annunziata CM
    Cancer; 2016 Feb; 122(4):588-597. PubMed ID: 26566079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the apoptotic machinery in pancreatic cancers using small-molecule antagonists of the X-linked inhibitor of apoptosis protein.
    Karikari CA; Roy I; Tryggestad E; Feldmann G; Pinilla C; Welsh K; Reed JC; Armour EP; Wong J; Herman J; Rakheja D; Maitra A
    Mol Cancer Ther; 2007 Mar; 6(3):957-66. PubMed ID: 17339366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lysosomal membrane permeabilization is an early event in Sigma-2 receptor ligand mediated cell death in pancreatic cancer.
    Hornick JR; Vangveravong S; Spitzer D; Abate C; Berardi F; Goedegebuure P; Mach RH; Hawkins WG
    J Exp Clin Cancer Res; 2012 May; 31(1):41. PubMed ID: 22551149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor activity of a novel homodimeric SMAC mimetic in ovarian carcinoma.
    Gatti L; De Cesare M; Ciusani E; Corna E; Arrighetti N; Cominetti D; Belvisi L; Potenza D; Moroni E; Vasile F; Lecis D; Delia D; Castiglioni V; Scanziani E; Seneci P; Zaffaroni N; Perego P
    Mol Pharm; 2014 Jan; 11(1):283-93. PubMed ID: 24256025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteasome inhibitors and Smac mimetics cooperate to induce cell death in diffuse large B-cell lymphoma by stabilizing NOXA and triggering mitochondrial apoptosis.
    Dietz A; Dalda N; Zielke S; Dittmann J; van Wijk SJL; Vogler M; Fulda S
    Int J Cancer; 2020 Sep; 147(5):1485-1498. PubMed ID: 32170726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiosensitization of head and neck squamous cell carcinoma by a SMAC-mimetic compound, SM-164, requires activation of caspases.
    Yang J; McEachern D; Li W; Davis MA; Li H; Morgan MA; Bai L; Sebolt JT; Sun H; Lawrence TS; Wang S; Sun Y
    Mol Cancer Ther; 2011 Apr; 10(4):658-69. PubMed ID: 21282353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel treatment option for MUC16-positive malignancies with the targeted TRAIL-based fusion protein Meso-TR3.
    Garg G; Gibbs J; Belt B; Powell MA; Mutch DG; Goedegebuure P; Collins L; Piwnica-Worms D; Hawkins WG; Spitzer D
    BMC Cancer; 2014 Jan; 14():35. PubMed ID: 24447304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design of small-molecule peptidic and nonpeptidic Smac mimetics.
    Sun H; Nikolovska-Coleska Z; Yang CY; Qian D; Lu J; Qiu S; Bai L; Peng Y; Cai Q; Wang S
    Acc Chem Res; 2008 Oct; 41(10):1264-77. PubMed ID: 18937395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. XIAP gene downregulation by small interfering RNA inhibits proliferation, induces apoptosis, and reverses the cisplatin resistance of ovarian carcinoma.
    Ma JJ; Chen BL; Xin XY
    Eur J Obstet Gynecol Reprod Biol; 2009 Oct; 146(2):222-6. PubMed ID: 19758744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SM-164: a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1/2 and XIAP.
    Lu J; Bai L; Sun H; Nikolovska-Coleska Z; McEachern D; Qiu S; Miller RS; Yi H; Shangary S; Sun Y; Meagher JL; Stuckey JA; Wang S
    Cancer Res; 2008 Nov; 68(22):9384-93. PubMed ID: 19010913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitor of apoptosis proteins as therapeutic targets in multiple myeloma.
    Ramakrishnan V; Painuly U; Kimlinger T; Haug J; Rajkumar SV; Kumar S
    Leukemia; 2014 Jul; 28(7):1519-28. PubMed ID: 24402161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.